Lamotrigine - GSK
Alternative Names: 430C78; BW 430C; Labileno; Lamactil; Lamictal; Lamictin; LamitrinLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Antidepressants; Antiepileptic drugs; Chlorobenzenes; Mood stabilisers; Small molecules; Triazines
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bipolar disorders; Lennox-Gastaut syndrome; Partial epilepsies; Tonic-clonic epilepsy
- Discontinued Absence epilepsy; Diabetic neuropathies; Neuropathic pain; Schizophrenia
Most Recent Events
- 28 Aug 2019 No recent reports on development identified - Phase-III for Absence epilepsy (In adolescents, In children, Monotherapy, Newly diagnosed) in Japan (PO)
- 28 Aug 2019 No recent reports on development identified - Phase-III for Absence epilepsy (In adolescents, In children, Monotherapy, Newly diagnosed) in South Korea (PO)
- 28 Aug 2019 No recent reports on development identified - Phase-III for Partial epilepsies (In adolescents, In adults, Monotherapy, Newly diagnosed, Recurrent) in South Korea (PO)